Poor immune response to inactivated COVID-19 vaccine in patients with hypertension

Abstract

PurposeThe safety and efficacy of vaccination in people with hypertension (HTN) is important. There are currently a few data on the immunogenicity and safety of inactivated SARS-CoV-2 vaccinations in hypertension patients.MethodsAfter receiving a two-dose immunization, 94 hypertension adult patients and 74 healthy controls (HCs) in this study, the evaluation included looking at antibodies (Abs) against receptor binding domain (RBD) IgG, SARS-CoV-2 neutralizing antibodies (NAbs), RBD-specific B cells, and memory B cells (MBCs).ResultsThere was no discernible difference in the overall adverse events (AEs) over the course of 7 or 30 days between HTN patients and HCs. HTN patients had lower frequencies of RBD-specific memory B cells and the seropositivity rates and titers of Abs compared with HCs (all, p < 0.05). HTN patients with cardiovascular and cerebrovascular conditions (CCVD) have lower titers of CoV-2 NAb than in HCs. The titers of both Abs in HTN declined gradually over time.ConclusionInactivated COVID-19 vaccinations were safe in hypertension patients; however humoral immune was limited, especially merged CCVD and declined gradually over time.

Temporal Trends in SARS-CoV-2 Antibody Levels Among COVID-19 Patients in Kerala During the First Wave and Pre-vaccination Period

“…We found that the IgG response was higher in patients who required hospitalization, oxygen therapy, ICU admission, or developed acute respiratory distress syndrome (ARDS) than in those who did not. This is in line with previous studies that showed that the IgG response was associated with the disease severity and the need for intensive care [ 25 ]. It is possible that the IgG response is a marker of the immune activation, rather than a causal factor of the disease outcome.…”